Lenalidomide (LEN) In Lower-Risk Myelodysplastic Syndromes (MDS) with Karyotypes Other Than Deletion 5q and Refractory to Erythropoiesis-Stimulating Agents (ESAs).

被引：0

作者：

Sibon, David ^{[1
]}

Cannas, Giovanna ^{[2
]}

Barraco, Fiorenza ^{[2
]}

Prebet, Thomas ^{[3
]}

Vey, Norbert ^{[4
]}

Banos, Anne ^{[5
]}

Besson, Caroline ^{[6
]}

Corm, Selim ^{[7
]}

Blanc, Michel ^{[7
]}

Slama, Borhane ^{[8
]}

Perrier, Herve ^{[2
]}

Fenaux, Pierre ^{[9
]}

Wattel, Eric ^{[2
]}

机构：

[1] GFM, Paris, France

[2] GFM, Lyon, France

[3] Inst J Paoli I Calmettes, Dept Hematol, F-13009 Marseille, France

[4] Hop Paoli Calmettes, Marseille, France

[5] GFM, Bayonne, France

[6] Univ Paris 11, CHU Bicetre, INSERM, U1012, Le Kremlin Bicetre, France

[7] GFM, Chambery, France

[8] GFM, Avignon, France

[9] Univ Paris 13, Hop Avicenne, Serv Hematol Clin, Bobigny, France

来源：

BLOOD | 2010年 / 116卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1632 / 1632

页数：1

共 50 条

[41] The role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromes
Melchert, Magda
Kale, Vishakha
List, Alan
CURRENT OPINION IN HEMATOLOGY, 2007, 14 (02) : 123 - 129
[42] Clinical outcomes and healthcare resource utilization (HCRU) in patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS) reinitiating erythropoiesis-stimulating agents (ESAs) following previous ESA treatment.
Garcia-Manero, Guillermo
Matsuno, Rayna K.
McBride, Ali
Brown, Thomas D.
Idryo, Danny
Broome, Ronda
Herriman, Autumn
Johnson, Tiffany
Wilkinson, Kristiana
Walters, Sheetal
Schrag, Andrew
Johanson, Colden
Izano, Monika A.
Mukherjee, Sudipto
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[43] Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1-risk myelodysplastic syndromes with karyotypes other than deletion 5q
Raza, Azra
Reeves, James A.
Feldman, Eric J.
Dewald, Gordon W.
Bennett, John M.
Deeg, Joachim
Dreisbach, Luke
Schiffer, Charles A.
Stone, Richard M.
Greenberg, Peter L.
Curtin, Peter T.
Klimek, Virginia M.
Shammo, Jamile M.
Thomas, Deborah
Knight, Robert D.
Schmidt, Michele
Wride, Kenton
Zeldis, Jerome B.
List, Alan F.
BLOOD, 2008, 111 (01) : 86 - 93
[44] Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients
Valeria Santini
Pierre Fenaux
Aristoteles Giagounidis
Uwe Platzbecker
Alan F. List
Torsten Haferlach
Jim Zhong
Chengqing Wu
Konstantinos Mavrommatis
C. L. Beach
Kyle J. MacBeth
Antonio Almeida
Leukemia, 2021, 35 : 897 - 900
[45] Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients
Santini, Valeria
Fenaux, Pierre
Giagounidis, Aristoteles
Platzbecker, Uwe
List, Alan F.
Haferlach, Torsten
Zhong, Jim
Wu, Chengqing
Mavrommatis, Konstantinos
Beach, C. L.
MacBeth, Kyle J.
Almeida, Antonio
LEUKEMIA, 2021, 35 (03) : 897 - 900
[46] Improvement of Patient-Reported Fatigue in IMerge Phase 3 Trial of Imetelstat vs Placebo in Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory/Ineligible for Erythropoiesis-Stimulating Agents
Sekeres, Mikkael
Santini, Valeria
Diez-Campelo, Maria
Komrokji, Rami
Fenaux, Pierre
Savona, Michael
Madanat, Yazan
Valcarcel-Ferreiras, David
Illmer, Thomas
Jonasova, Anna
Belohlavkova, Petra
Regnault, Antoine
Creel, Kristin
Sengupta, Nishan
Sherman, Laurie
Berry, Tymara
Dougherty, Souria
Shah, Sheetal
Xia, Qi
Sun, Libo
Wan, Ying
Huang, Fei
Ikin, Annat
Navada, Shymala
Feller, Faye
Zeidan, Amer
Platzbecker, Uwe
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S373 - S373
[47] Efficacy and Safety of Lenalidomide (LEN) Versus Placebo (PBO) in RBC-Transfusion Dependent (TD) Patients (Pts) with IPSS Low/Intermediate (Int-1)-Risk Myelodysplastic Syndromes (MDS) without Del(5q) and Unresponsive or Refractory to Erythropoiesis-Stimulating Agents (ESAs): Results from a Randomized Phase 3 Study (CC-5013-MDS-005)
Santini, Valeria
Almeida, Antonio
Giagounidis, Aristoteles
Groepper, Stephanie
Jonasova, Anna
Vey, Norbert
Mufti, Ghulam J.
Buckstein, Rena
Mittelman, Moshe
Platzbecker, Uwe
Shpilberg, Ofer
Ram, Ron
del Canizo, Consuelo
Gattermann, Norbert
Ozawa, Keiya
Zhong, Jim
Seguy, Francis
Hoenekopp, Albert
Beach, C. L.
Fenaux, Pierre
BLOOD, 2014, 124 (21)
[48] Safety of Lenalidomide (LEN) 10mg in Non-Del(5q) Versus Del(5q) in the Treatment of Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (MDS): Pooled Analysis of Treatment-Emergent Adverse Events (TEAEs)
Almeida, Antonio
Santini, Valeria
Croepper, Stefanie
Jonasova, Anna
Vey, Norbert
Giagounidis, Aristoteles
Hellstrom-Lindberg, Eva
Mufti, Ghulam J.
Sanz, Guillermo
Skikne, Barry
Hoenekopp, Albert
Seguy, Francis
Zhong, Jianhua
Fenaux, Pierre
BLOOD, 2015, 126 (23)
[49] Outcomes and effect of somatic mutations after erythropoiesis stimulating agents in patients with lower-risk myelodysplastic syndromes
Caballero, Juan Carlos
Davila, Julio
Lopez-Pavia, Maria
Such, Esperanza
Bernal, Teresa
Ramos, Fernando
Calabuig, Marisa
Sanchez, Jesus Maria Hernandez
Pomares, Helena
Barba, Mercedes Sanchez
Abaigar, Maria
Gonzalez, Bernardo
Merchan, Brayan
Sancho-Tello, Reyes
Callejas, Marta
Munoz-Novas, Carolina
Cervero, Carlos
Sanz, Guillermo
Rivas, Jesus Maria Hernandez
Campelo, Maria Diez
THERAPEUTIC ADVANCES IN HEMATOLOGY, 2024, 15
[50] Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes
Komrokji, R. S.
List, A. F.
ANNALS OF ONCOLOGY, 2016, 27 (01) : 62 - 68

← 1 2 3 4 5 →